WallStSmart

Churchill Capital Corp XI Class A Ordinary Shares (CCXI)vsEmisphere Technologies Inc (EMIS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Churchill Capital Corp XI Class A Ordinary Shares generates 3471% more annual revenue ($37.28M vs $1.04M). CCXI leads profitability with a 0.0% profit margin vs -205.8%. CCXI earns a higher WallStSmart Score of 32/100 (F).

CCXI

Avoid

32

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 5.0

EMIS

Avoid

13

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 5.0Quality: 3.8
Piotroski: 5/9Altman Z: -119.78

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCXI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
549.0%10/10

Revenue surging 549.0% year-over-year

EMIS0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CCXI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-47.0%2/10

ROE of -47.0% — below average capital efficiency

Free Cash FlowQuality
$-26.53M2/10

Negative free cash flow — burning cash

EMIS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$497.77M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-40.5%2/10

Revenue declined 40.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCXI

The strongest argument for CCXI centers on Revenue Growth. Revenue growth of 549.0% demonstrates continued momentum.

Bull Case : EMIS

EMIS has a balanced fundamental profile.

Bear Case : CCXI

The primary concerns for CCXI are EPS Growth, Profit Margin, Return on Equity.

Bear Case : EMIS

The primary concerns for EMIS are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

CCXI profiles as a hypergrowth stock while EMIS is a turnaround play — different risk/reward profiles.

EMIS carries more volatility with a beta of 1.41 — expect wider price swings.

CCXI is growing revenue faster at 549.0% — sustainability is the question.

EMIS generates stronger free cash flow (-1M), providing more financial flexibility.

Bottom Line

CCXI scores higher overall (32/100 vs 13/100) and 549.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Churchill Capital Corp XI Class A Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.

Emisphere Technologies Inc

FINANCIAL SERVICES · SHELL COMPANIES · USA

Emisphere Technologies, Inc. is a commercial stage pharmaceutical and drug delivery company in the United States. The company is headquartered in Roseland, New Jersey.

Visit Website →

Want to dig deeper into these stocks?